GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004206010 | Cervix | CC | wound healing | 109/2311 | 422/18723 | 1.84e-14 | 1.57e-11 | 109 |
GO:000701510 | Cervix | CC | actin filament organization | 109/2311 | 442/18723 | 4.92e-13 | 2.45e-10 | 109 |
GO:00453339 | Cervix | CC | cellular respiration | 66/2311 | 230/18723 | 2.07e-11 | 5.39e-09 | 66 |
GO:009013210 | Cervix | CC | epithelium migration | 90/2311 | 360/18723 | 2.45e-11 | 6.11e-09 | 90 |
GO:00016679 | Cervix | CC | ameboidal-type cell migration | 110/2311 | 475/18723 | 2.66e-11 | 6.36e-09 | 110 |
GO:001063110 | Cervix | CC | epithelial cell migration | 89/2311 | 357/18723 | 3.72e-11 | 8.54e-09 | 89 |
GO:003297010 | Cervix | CC | regulation of actin filament-based process | 96/2311 | 397/18723 | 4.00e-11 | 8.54e-09 | 96 |
GO:009013010 | Cervix | CC | tissue migration | 90/2311 | 365/18723 | 5.42e-11 | 1.05e-08 | 90 |
GO:190290310 | Cervix | CC | regulation of supramolecular fiber organization | 92/2311 | 383/18723 | 1.49e-10 | 2.48e-08 | 92 |
GO:002240710 | Cervix | CC | regulation of cell-cell adhesion | 103/2311 | 448/18723 | 1.78e-10 | 2.87e-08 | 103 |
GO:004578510 | Cervix | CC | positive regulation of cell adhesion | 101/2311 | 437/18723 | 1.96e-10 | 3.08e-08 | 101 |
GO:003295610 | Cervix | CC | regulation of actin cytoskeleton organization | 86/2311 | 358/18723 | 5.90e-10 | 7.51e-08 | 86 |
GO:00421108 | Cervix | CC | T cell activation | 107/2311 | 487/18723 | 1.24e-09 | 1.46e-07 | 107 |
GO:00508638 | Cervix | CC | regulation of T cell activation | 80/2311 | 329/18723 | 1.28e-09 | 1.47e-07 | 80 |
GO:00060919 | Cervix | CC | generation of precursor metabolites and energy | 105/2311 | 490/18723 | 7.40e-09 | 6.61e-07 | 105 |
GO:00071598 | Cervix | CC | leukocyte cell-cell adhesion | 85/2311 | 371/18723 | 8.27e-09 | 7.07e-07 | 85 |
GO:003367410 | Cervix | CC | positive regulation of kinase activity | 101/2311 | 467/18723 | 8.66e-09 | 7.22e-07 | 101 |
GO:00071738 | Cervix | CC | epidermal growth factor receptor signaling pathway | 36/2311 | 108/18723 | 1.04e-08 | 8.44e-07 | 36 |
GO:00159809 | Cervix | CC | energy derivation by oxidation of organic compounds | 74/2311 | 318/18723 | 3.83e-08 | 2.53e-06 | 74 |
GO:011005310 | Cervix | CC | regulation of actin filament organization | 67/2311 | 278/18723 | 4.01e-08 | 2.54e-06 | 67 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0491913 | Liver | HCC | Thyroid hormone signaling pathway | 75/4020 | 121/8465 | 8.76e-04 | 3.38e-03 | 1.88e-03 | 75 |
hsa042103 | Liver | HCC | Apoptosis | 83/4020 | 136/8465 | 9.51e-04 | 3.58e-03 | 1.99e-03 | 83 |
hsa0516031 | Liver | HCC | Hepatitis C | 94/4020 | 157/8465 | 1.11e-03 | 4.10e-03 | 2.28e-03 | 94 |
hsa0516431 | Liver | HCC | Influenza A | 101/4020 | 171/8465 | 1.41e-03 | 5.07e-03 | 2.82e-03 | 101 |
hsa0401211 | Liver | HCC | ErbB signaling pathway | 54/4020 | 85/8465 | 2.02e-03 | 7.07e-03 | 3.93e-03 | 54 |
hsa0421311 | Liver | HCC | Longevity regulating pathway - multiple species | 41/4020 | 62/8465 | 2.30e-03 | 7.86e-03 | 4.37e-03 | 41 |
hsa0493311 | Liver | HCC | AGE-RAGE signaling pathway in diabetic complications | 62/4020 | 100/8465 | 2.35e-03 | 7.95e-03 | 4.42e-03 | 62 |
hsa052033 | Liver | HCC | Viral carcinogenesis | 117/4020 | 204/8465 | 2.68e-03 | 8.98e-03 | 5.00e-03 | 117 |
hsa0522211 | Liver | HCC | Small cell lung cancer | 57/4020 | 92/8465 | 3.54e-03 | 1.12e-02 | 6.22e-03 | 57 |
hsa0522311 | Liver | HCC | Non-small cell lung cancer | 46/4020 | 72/8465 | 3.61e-03 | 1.12e-02 | 6.22e-03 | 46 |
hsa0516731 | Liver | HCC | Kaposi sarcoma-associated herpesvirus infection | 111/4020 | 194/8465 | 3.78e-03 | 1.16e-02 | 6.45e-03 | 111 |
hsa0407111 | Liver | HCC | Sphingolipid signaling pathway | 72/4020 | 121/8465 | 5.01e-03 | 1.47e-02 | 8.18e-03 | 72 |
hsa0521411 | Liver | HCC | Glioma | 47/4020 | 75/8465 | 5.67e-03 | 1.62e-02 | 9.02e-03 | 47 |
hsa0467052 | Liver | HCC | Leukocyte transendothelial migration | 68/4020 | 114/8465 | 5.79e-03 | 1.64e-02 | 9.15e-03 | 68 |
hsa051421 | Liver | HCC | Chagas disease | 61/4020 | 102/8465 | 8.04e-03 | 2.17e-02 | 1.21e-02 | 61 |
hsa0492611 | Liver | HCC | Relaxin signaling pathway | 75/4020 | 129/8465 | 9.33e-03 | 2.46e-02 | 1.37e-02 | 75 |
hsa0466611 | Liver | HCC | Fc gamma R-mediated phagocytosis | 58/4020 | 97/8465 | 9.65e-03 | 2.52e-02 | 1.40e-02 | 58 |
hsa0152131 | Liver | HCC | EGFR tyrosine kinase inhibitor resistance | 48/4020 | 79/8465 | 1.19e-02 | 2.99e-02 | 1.66e-02 | 48 |
hsa015221 | Liver | HCC | Endocrine resistance | 58/4020 | 98/8465 | 1.28e-02 | 3.19e-02 | 1.78e-02 | 58 |
hsa049171 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PIK3CA | SNV | Missense_Mutation | rs121913273 | c.1624G>A | p.Glu542Lys | p.E542K | P42336 | protein_coding | deleterious(0.04) | probably_damaging(0.912) | TCGA-3C-AALK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
PIK3CA | SNV | Missense_Mutation | | c.3012G>T | p.Met1004Ile | p.M1004I | P42336 | protein_coding | deleterious(0.01) | benign(0.047) | TCGA-3C-AALK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
PIK3CA | SNV | Missense_Mutation | rs121913279 | c.3140A>T | p.His1047Leu | p.H1047L | P42336 | protein_coding | tolerated(0.44) | benign(0.007) | TCGA-5L-AAT0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PIK3CA | SNV | Missense_Mutation | rs121913287 | c.263G>A | p.Arg88Gln | p.R88Q | P42336 | protein_coding | tolerated(0.06) | probably_damaging(0.971) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
PIK3CA | SNV | Missense_Mutation | rs121913273 | c.1624G>A | p.Glu542Lys | p.E542K | P42336 | protein_coding | deleterious(0.04) | probably_damaging(0.912) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
PIK3CA | SNV | Missense_Mutation | rs867262025 | c.2176N>A | p.Glu726Lys | p.E726K | P42336 | protein_coding | tolerated(0.36) | benign(0.396) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PIK3CA | SNV | Missense_Mutation | rs121913279 | c.3140N>G | p.His1047Arg | p.H1047R | P42336 | protein_coding | tolerated(0.11) | benign(0.085) | TCGA-A1-A0SI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PIK3CA | SNV | Missense_Mutation | rs121913273 | c.1624N>A | p.Glu542Lys | p.E542K | P42336 | protein_coding | deleterious(0.04) | probably_damaging(0.912) | TCGA-A2-A04N-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | cytoxan | SD |
PIK3CA | SNV | Missense_Mutation | rs121913287 | c.263N>A | p.Arg88Gln | p.R88Q | P42336 | protein_coding | tolerated(0.06) | probably_damaging(0.971) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
PIK3CA | SNV | Missense_Mutation | rs121913281 | c.3139N>T | p.His1047Tyr | p.H1047Y | P42336 | protein_coding | tolerated(1) | benign(0) | TCGA-A2-A04T-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | inhibitor | 249565638 | ALPELISIB | |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | inhibitor | INK-1117 | INK-1117 | |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | inhibitor | 354702297 | GSK-1059615 | |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | | MS417 | | 26058079 |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | | Olaparib | OLAPARIB | 26909613 |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | | NSC-79888 | CHEMBL1939433 | 22212721 |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | | CH-5132799 | PA-799 | |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | inhibitor | 381118806 | ACALISIB | |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | | ALPELISIB | ALPELISIB | 31091374,24608574 |
5290 | PIK3CA | PHOSPHATIDYLINOSITOL 3 KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, KINASE, ENZYME, SERINE THREONINE KINASE, DRUG RESISTANCE | | Linsitinib | LINSITINIB | 27196766 |